How to Get Lantus in Vermont: Prescriptions, Telehealth, and Pharmacy Access

What Is Lantus and Why Do Vermont Patients Need It?

Lantus is a long-acting, recombinant human insulin analog that provides steady basal insulin coverage over approximately 24 hours with minimal peak effect. The FDA approved Lantus for adults with type 1 and type 2 diabetes in April 2000, and for pediatric patients aged 6 and older with type 1 diabetes in subsequent labeling updates. The current FDA prescribing information is available through the FDA accessdata portal.

Roughly 12.4% of Vermont adults have diagnosed diabetes, according to the CDC's 2023 State Indicator data. That translates to approximately 80,000 Vermonters managing the condition, many of whom require basal insulin for glycemic control.

Why Basal Insulin Matters in Vermont's Rural Context

Vermont is among the most rural states in the country. About 61% of its population lives outside metropolitan statistical areas, creating real distance barriers between patients and endocrinologists. Telehealth has closed that gap meaningfully for insulin prescribing.

The landmark ORIGIN trial (N=12,537, median follow-up 6.2 years) published in the New England Journal of Medicine found that insulin glargine titrated to a fasting glucose target of 95 mg/dL or less did not increase cardiovascular event rates compared with standard care, with a hazard ratio of 1.02 (95% CI 0.94 to 1.11). ORIGIN, NEJM 2012 This evidence base supports long-term Lantus use as a safe basal strategy across a wide patient population.

Insulin Glargine Formulations Available in Vermont Pharmacies

Vermont retail and mail-order pharmacies stock several insulin glargine formulations:

• Lantus (insulin glargine-yfgn, 100 units/mL, vials and SoloStar pens)
• Toujeo (insulin glargine-yfgn, 300 units/mL, SoloStar and Max SoloStar pens)
• Basaglar (insulin glargine-yfgn, 100 units/mL, KwikPen, biosimilar)
• Rezvoglar (insulin glargine-aglr, 100 units/mL, KwikPen, biosimilar)
• Semglee (insulin glargine-yfgn, 100 units/mL, vials and pens, interchangeable biosimilar)

Semglee received FDA interchangeable biosimilar designation in July 2021, meaning a Vermont pharmacist can substitute it for Lantus without a new prescription unless the prescriber writes "dispense as written." Patients who have been stable on brand Lantus should tell their pharmacist if they want to stay on the originator product.

Who Can Prescribe Lantus in Vermont?

Any Vermont-licensed prescriber with prescriptive authority may write for Lantus. Vermont does not restrict basal insulin prescribing to endocrinologists or diabetes specialists. Under Vermont statutes (26 V.S.A. Chapter 33 for physicians, Chapter 28 for advanced practice registered nurses), the following provider types hold full prescriptive authority for insulin:

• Medical doctors (MD) and doctors of osteopathic medicine (DO)
• Advanced practice registered nurses (APRN), including nurse practitioners (NP), who hold full independent prescriptive authority in Vermont
• Physician assistants (PA), who prescribe under a delegation agreement
• Certified nurse-midwives (CNM) within their scope of practice

Vermont is a full practice authority state for NPs. That means a Vermont NP can open, manage, and close a diabetes episode, including basal insulin initiation and titration, without physician oversight. The American Association of Nurse Practitioners maintains updated state practice environment data.

Telehealth Prescribing: Is a Vermont Prescriber Required?

For a telehealth visit to generate a valid Vermont Lantus prescription, the prescriber must hold an active Vermont license or a qualifying Interstate Medical Licensure Compact (IMLC) license that includes Vermont. Vermont joined the IMLC in 2015.

Telehealth prescribers must establish a valid patient-provider relationship before writing for any prescription medication under Vermont law. A brief video or audio visit that includes a clinical history review, current medication reconciliation, and review of relevant labs satisfies this requirement for most payers and platforms.

Telehealth platforms operating in Vermont and offering endocrinology or primary care services include national telehealth companies as well as Vermont-specific systems such as the UVM Health Network's MyChart telehealth integration. The Health Resources and Services Administration maintains a telehealth policy tracker relevant to state-by-state prescribing.

What Labs Are Needed Before Starting Lantus in Vermont?

A prescriber evaluating a patient for Lantus initiation will typically order or review the following before writing the prescription:

Required Baseline Labs

• Hemoglobin A1c (HbA1c): Establishes baseline glycemic control and guides starting dose. The American Diabetes Association 2024 Standards of Care recommend an HbA1c target of <7% for most non-pregnant adults with diabetes. ADA Standards of Care 2024
• Fasting plasma glucose (FPG): Guides titration target; ORIGIN used a fasting glucose goal of <95 mg/dL. NEJM 2012 ORIGIN
• Basic metabolic panel (BMP): Screens for renal impairment, which affects concurrent oral agent dosing, and checks potassium, since insulin drives potassium intracellularly.
• Complete blood count (CBC): Identifies anemia that could artifactually lower HbA1c readings.

Labs That Support Prior Authorization

Vermont Medicaid and most commercial insurers require documented lab evidence to approve Lantus. A prior authorization request without recent HbA1c (generally within 90 days) will typically be rejected. Vermont Medicaid pharmacy benefit policy is administered through the Department of Vermont Health Access.

Providers submitting a PA should include:

1. HbA1c value and date
2. Current diabetes medications and failure or contraindication documentation
3. Prescriber attestation of diagnosis (ICD-10 E10.x for T1D or E11.x for T2D)
4. Any relevant comorbidities such as chronic kidney disease that restrict oral agent use

Labs for Ongoing Monitoring

After initiation, the ADA recommends HbA1c testing every 3 months until target is achieved, then every 6 months. ADA 2024 Standards Self-monitored fasting blood glucose values should be reviewed at each visit to guide titration. The standard self-titration algorithm from the INSIGHT trial used 2-unit weekly dose increments targeting fasting glucose of 80 to 110 mg/dL. INSIGHT trial, Diabetologia 2007

How to Get a Lantus Prescription in Vermont: Step-by-Step

Getting a Lantus prescription in Vermont follows a predictable clinical pathway whether the visit is in-person or via telehealth.

Step 1: Establish Care With a Vermont Prescriber

Options include:

• Primary care physician or NP at a Vermont federally qualified health center (FQHC), such as Community Health Centers of Burlington
• Endocrinology referral through UVM Medical Center or Dartmouth Health (which serves southern Vermont)
• Telehealth visit through a platform with a Vermont-licensed prescriber

For new-to-care patients, a telehealth platform can schedule an initial visit within 24 to 72 hours. The visit covers symptom history, current medications, previous insulin use, and lab review.

Step 2: Complete the Clinical Visit and Lab Review

The prescriber reviews HbA1c and fasting glucose. Patients who already have labs from a primary care provider can share records in advance to shorten the visit. For telehealth visits, most platforms accept uploaded lab PDFs through a patient portal.

Step 3: Receive the Prescription and Choose a Pharmacy

Vermont law allows e-prescribing to any in-state or out-of-state pharmacy licensed to serve Vermont patients. Common pharmacy options include:

• CVS and Rite Aid locations in Burlington, Montpelier, Rutland, and St. Johnsbury
• Hannaford and Shaw's grocery pharmacies statewide
• Mail-order pharmacies (Express Scripts, OptumRx, CVS Caremark)
• 503A compounding pharmacies for patients who need non-standard concentrations

Step 4: Prior Authorization (If Insurance Requires It)

If the prescriber's office submits a PA, Vermont Medicaid processes standard PA requests within 3 business days. Expedited reviews, for situations involving clinical urgency, must be completed within 24 hours under federal Medicaid guidelines. 42 CFR 438.210 governs Medicaid managed care prior authorization timelines.

Step 5: First Fill Timeline

• In-stock retail pharmacy: same day to 24 hours after PA approval
• Mail-order pharmacy: 3 to 7 business days
• 503A compounding pharmacy: 5 to 10 business days

Prior Authorization in Vermont: What Prescribers and Patients Should Know

Vermont Medicaid (Green Mountain Care) covers Lantus and biosimilar insulin glargine products for both type 1 and type 2 diabetes with prior authorization. Commercial plans sold on the Vermont Health Connect marketplace follow similar PA requirements.

Documentation Checklist for PA Submission

The following framework reflects the documentation set that satisfies most Vermont Medicaid and commercial PA requests for insulin glargine:

| Document | Specification | |---|---| | Diagnosis confirmation | ICD-10 E10.x or E11.x with date of diagnosis | | Recent HbA1c | Value and date, within 90 days preferred | | Trial of oral agents | For T2D: documented metformin use or contraindication | | Prescriber notes | Clinical rationale for basal insulin over NPH or alternatives | | Formulary step-through | Evidence biosimilar was considered (some plans require) | | Patient identity | Vermont Medicaid ID or commercial member ID |

Prescribers who submit PA requests with all six documentation elements have a significantly higher first-pass approval rate than those who submit incomplete requests. Vermont's Act 76 (2023) requires insurers to respond to standard PA requests within 72 hours and urgent requests within 24 hours. Vermont legislature Act 76 summary

Appeals Process

If a PA is denied, Vermont law provides a two-level internal appeal process followed by an independent external review. The Vermont Department of Financial Regulation oversees insurer appeals. Patients experiencing an urgent need for insulin can request an expedited appeal, which must be resolved within 72 hours.

Transferring an Existing Lantus Prescription to Vermont

Patients moving to Vermont or establishing a Vermont address while keeping an out-of-state prescriber have two practical options.

Option 1: Transfer the Existing Prescription to a Vermont Pharmacy

A Vermont pharmacist can contact the dispensing pharmacy in the originating state to transfer a remaining refill. Vermont law (18 V.S.A. Section 4215) permits prescription transfers for non-Schedule II substances. Lantus is not a controlled substance, so transfers are straightforward. The Vermont pharmacist will need the original prescription number, original pharmacy name and phone, and the patient's date of birth.

Option 2: Request a New Prescription From a Vermont Provider

If the out-of-state prescription has no refills remaining or the prescriber is not licensed in Vermont, the patient needs a new prescription from a Vermont-licensed provider. A telehealth visit is the fastest path. Records from the prior prescriber documenting current Lantus dose and recent labs can shorten the new visit to 15 to 20 minutes.

The Vermont Board of Medical Practice maintains licensing verification for physicians.

503A Compounding Pharmacies in Vermont

Vermont-licensed 503A pharmacies may compound insulin glargine for patients with documented clinical need for a non-commercial formulation. Permitted 503A activities include:

• Diluted concentrations for pediatric patients or those requiring very small doses
• Preservative-free formulations for patients with documented excipient sensitivity
• Combined formulations when clinically appropriate and supported by prescriber documentation

503A pharmacies compound on a patient-specific prescription basis. FDA guidance on 503A and 503B compounding pharmacies clarifies that 503A facilities are regulated primarily by state boards of pharmacy rather than FDA manufacturing standards. The Vermont Board of Pharmacy licenses and inspects 503A compounding facilities operating in the state.

Patients considering a 503A-compounded insulin glargine product should confirm with their prescriber that the compounded formulation will carry the same IU-per-mL concentration they are accustomed to, since dosing errors have been associated with concentration mismatches. FDA MedWatch has documented insulin concentration errors.

Lantus Cost and Savings Programs for Vermont Residents

Cost is a real barrier. A 10-mL vial of brand Lantus carries a retail cash price near $300 in Vermont pharmacies as of 2025.

Sanofi Valyou Savings Program

Sanofi offers the Valyou Savings Program for commercially insured patients who qualify. Eligible patients may pay as little as $99 per month for Sanofi insulins including Lantus. Sanofi's patient assistance information is available through NeedyMeds.

Vermont Insulin Affordability Act

Vermont passed Act 175 in 2018, capping out-of-pocket insulin costs for state-regulated commercial plans at $100 per 30-day supply. Vermont legislature insulin affordability summary The cap applies to plans regulated by the Vermont Department of Financial Regulation. Self-insured employer plans governed by ERISA are not subject to the state cap.

Vermont Medicaid and Dr. Dynasaur

Vermont Medicaid covers Lantus and biosimilar glargine products. Dr. Dynasaur covers children up to age 18 regardless of immigration status and extends coverage to young adults up to age 26 under specific income thresholds. Vermont Medicaid enrollment information

Biosimilar Cost Savings

Switching from brand Lantus to an FDA-interchangeable biosimilar such as Semglee can reduce out-of-pocket cost by 30 to 65% at most Vermont pharmacies, depending on plan formulary placement. FDA biosimilar substitution guidance Patients on fixed incomes who do not qualify for Medicaid often find the biosimilar route the most practical cost reduction strategy without needing a new clinical visit.

Dosing Basics Vermont Prescribers Use for Lantus Initiation

Vermont prescribers, whether in-person or via telehealth, generally follow one of two published initiation protocols.

Type 2 Diabetes Initiation

The ADA 2024 Standards recommend starting basal insulin at 10 units per day or 0.1 to 0.2 units per kilogram per day, whichever is lower, and titrating by 2 units every 3 days until fasting glucose reaches the patient's individual target. ADA 2024 Standards of Care

Type 1 Diabetes Initiation

For type 1 diabetes, total daily insulin dose typically starts at 0.4 to 0.5 units per kilogram per day, split roughly 50% basal (Lantus) and 50% bolus (a rapid-acting insulin). The Lantus component is given once daily, most often at the same time each day. Endocrine Society Clinical Practice Guideline on T1D management

Lantus should not be mixed in the same syringe with any other insulin. A 2016 FDA Drug Safety Communication confirmed that mixing Lantus with other insulins changes the pharmacokinetic profile unpredictably. FDA Drug Safety Communications

Injection Technique

Lantus is injected subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites within the same region is recommended to reduce lipohypertrophy. The Endocrine Society notes that injection into lipohypertrophic tissue significantly impairs insulin absorption. Endocrine Society position on injection technique

Telehealth Lantus Prescribing in Vermont: What to Expect From Your First Visit

A telehealth first visit for Lantus initiation typically runs 20 to 40 minutes and covers the following:

• Chief complaint and diabetes history (type, year of diagnosis, prior insulin use)
• Review of uploaded or verbally reported lab values (HbA1c, FPG, BMP)
• Current medications and any contraindications to concurrent oral agents
• Blood glucose monitoring habits and equipment (glucometer or CGM)
• Patient education on injection technique, hypoglycemia recognition, and dose titration
• Discussion of pharmacy preference and whether PA will be needed

Most telehealth platforms that operate in Vermont can transmit an e-prescription to a Vermont pharmacy within minutes of visit completion. If PA is required, the prescriber's team submits the request the same business day. The patient typically receives a phone or portal notification of PA approval within 1 to 3 business days for commercial insurance and 3 to 5 business days for Vermont Medicaid.

The Agency for Healthcare Research and Quality has published guidance on telehealth quality for chronic disease management that applies directly to insulin prescribing workflows.